Arcturus Therapeutics

Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics

Placeholder

Arcturus Therapeutics

  • Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ TechnologyREAD MORE
  • Arcturus Therapeutics Expands Platform with STARR™ TechnologyREAD MORE
  • Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis FoundationREAD MORE
  • Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License AgreementREAD MORE
  • Synthetic GenomicsArcturus Therapeutics Announces Strategic Alliance with Synthetic Genomics, Inc. to develop self-amplifying RNA-based vaccines and therapeuticsREAD MORE

LUNAR®-mediated delivery of RNA into cells

LUNAR particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.

Upon entering the cytosol, the LUNAR formulations then become trapped in the endosomes.

With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR components.

Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.

LUNAR® lipid mediated delivery enables delivery of RNA medicines.

News & Events

  • May 21, 2020

    Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics

    • May 21 2020
    • 0
    read more
  • May 8, 2020

    Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)

    • May 8 2020
    • 0
    read more
  • May 7, 2020

    Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update

    • May 7 2020
    • 0
    read more
  • May 5, 2020

    Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020

    • May 5 2020
    • 0
    read more
  • May 4, 2020

    Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine

    • May 4 2020
    • 0
    read more
  • April 27, 2020

    Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate

    • April 27 2020
    • 0
    read more
  • April 21, 2020

    Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    • April 21 2020
    • 0
    read more
  • April 20, 2020

    Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology

    • April 20 2020
    • 0
    read more
  • April 16, 2020

    Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock

    • April 16 2020
    • 0
    read more